8-K Announcements
6Material company update
Jun 2, 2026·SEC
Material company update
May 21, 2026·SEC
Material company update
Jan 23, 2026·SEC
PetMed Express, Inc.(PETS)Earnings, Financials & Key Ratios
PETS•NASDAQ
Price updated Jun 19, 2026
AboutPetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.Show more
- Revenue$179M-21.1%
- EBITDA-$22M-499.9%
- Net Income-$57M-813.5%
- EPS (Diluted)-2.74-813.3%
- Gross Margin28.05%-7.9%
- EBITDA Margin-12.3%-607.0%
- Operating Margin-17.55%-2503.2%
- Net Margin-32%-1058.2%
- ROE-100.44%-1356.4%
PETS Key Insights
PetMed Express, Inc. (PETS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.3x book value
- ✓Efficient asset utilization: 2.2x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 10.0% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PETS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PETS Price & Volume
PetMed Express, Inc. (PETS) stock price & volume — 10-year historical chart
Loading chart...
PETS Growth Metrics
PetMed Express, Inc. (PETS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.67%
5 Years-10.02%
3 Years-11.31%
TTM-21.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-813.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-803.71%
Return on Capital
10 Years13.39%
5 Years-7.95%
3 Years-20.96%
Last Year-54.59%
PETS Recent Earnings
PetMed Express, Inc. (PETS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 2/12 qtrs (17%)
Q3 2026Latest
Jun 2, 2026Metric
Actual
Est
EPS
$0.19-5.6%
$0.18
Rev
$43M-17.7%
$52M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.50-733.3%
$0.06
Rev
$41M-24.8%
$54M
Q4 2025
Dec 19, 2025Metric
Actual
Est
EPS
$0.34-1600.0%
$0.02
Rev
$44M-36.0%
$69M
Q1 2025
Feb 10, 2025Metric
Actual
Est
EPS
$0.03-700.0%
$0.01
Rev
$53M-1.9%
$54M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 2, 2026 | $0.19vs $0.18-5.6% | $43Mvs $52M-17.7% |
| Q1 2026 | Feb 5, 2026 | $0.50vs $0.06-733.3% | $41Mvs $54M-24.8% |
| Q4 2025 | Dec 19, 2025 | $0.34vs $0.02-1600.0% | $44Mvs $69M-36.0% |
| Q1 2025 | Feb 10, 2025 | $0.03vs $0.01-700.0% | $53Mvs $54M-1.9% |
Based on last 12 quarters of dataView full earnings history →
PETS Peer Comparison
PetMed Express, Inc. (PETS) competitors in Digital Health and Online Pharmacy — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CHWY | 7.54B | 18.21 | 35.02 | 6.24% | 1.57% | 44.82% | 1.12 | |
 WOOF | 748.18M | 2.62 | 82.65 | -2.53% | -0.39% | -2.03% | 2.46 | |
 FRPT | 2.7B | 55.01 | 20.84 | 13.01% | 17.63% | 16.98% | 0.46 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 | |
 GOCO | 8.94M | 0.31 | -0.02 | -54.71% | -189.73% | -462.09% | ||
 RXRX | 1.44B | 3.23 | -2.24 | 26.92% | -8.44% | -54.32% | 0.07 | |
 ZTS | 33B | 78.71 | 13.07 | 2.28% | 27.79% | 62.41% | 2.85 |
Compare PETS vs Peers
PetMed Express, Inc. (PETS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PETS Income Statement
PetMed Express, Inc. (PETS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 273.8M | 283.42M | 284.13M | 303.58M | 273.42M | 256.58M | 274.1M | 226.97M | 179.02M |
Revenue Growth % | 9.88% | 3.51% | 0.25% | 6.85% | -9.94% | -6.16% | 6.83% | -17.19% | -21.13% |
Cost of Goods Sold | 175.99M | 188.1M | 202.88M | 219.27M | 198.08M | 185.84M | 196.38M | 157.84M | 128.81M |
COGS % of Revenue | 64.28% | 66.37% | 71.4% | 72.23% | 72.45% | 72.43% | 71.65% | 69.54% | 71.95% |
Gross Profit | 97.81M▲ 0% | 95.31M▼ 2.5% | 81.25M▼ 14.8% | 84.32M▲ 3.8% | 75.34M▼ 10.6% | 71.01M▼ 5.7% | 77.71M▲ 9.4% | 69.14M▼ 11.0% | 50.22M▼ 27.4% |
Gross Margin % | 35.72% | 33.63% | 28.6% | 27.77% | 27.55% | 27.68% | 28.35% | 30.46% | 28.05% |
Gross Profit Growth % | 23.32% | -2.55% | -14.76% | 3.78% | -10.65% | -5.74% | 9.43% | -11.03% | -27.37% |
Operating Expenses | 45.67M | 49.14M | 50.27M | 53.78M | 49.63M | 64.68M | 84.67M | 70.67M | 72.24M |
OpEx % of Revenue | 16.68% | 17.34% | 17.69% | 17.72% | 18.15% | 25.21% | 30.89% | 31.13% | 40.36% |
Selling, General & Admin | 43.55M | 46.91M | 48.01M | 49.93M | 49.63M | 68.9M | 79.75M | 62.43M | 72.24M |
SG&A % of Revenue | 15.9% | 16.55% | 16.9% | 16.45% | 18.15% | 26.85% | 29.1% | 27.5% | 40.36% |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 2.13M | 2.23M | 2.26M | 3.85M | 0 | -4.21M | 4.92M | 8.24M | 0 |
Operating Income | 52.14M▲ 0% | 46.17M▼ 11.4% | 30.98M▼ 32.9% | 30.53M▼ 1.4% | 25.71M▼ 15.8% | 6.55M▼ 74.5% | -6.96M▼ 206.3% | -1.53M▲ 78.0% | -31.41M▼ 1953.3% |
Operating Margin % | 19.04% | 16.29% | 10.9% | 10.06% | 9.4% | 2.55% | -2.54% | -0.67% | -17.55% |
Operating Income Growth % | 39.09% | -11.44% | -32.91% | -1.44% | -15.79% | -74.52% | -206.27% | 78.02% | -1953.27% |
EBITDA | 54.26M | 48.4M | 33.23M | 32.96M | 28.45M | 10.1M | 94K | 5.51M | -22.03M |
EBITDA Margin % | 19.82% | 17.08% | 11.7% | 10.86% | 10.4% | 3.94% | 0.03% | 2.43% | -12.3% |
EBITDA Growth % | 39.66% | -10.8% | -31.33% | -0.83% | -13.68% | -64.51% | -99.07% | 5760.64% | -499.85% |
D&A (Non-Cash Add-back) | 2.13M | 2.23M | 2.26M | 2.43M | 2.74M | 3.55M | 7.06M | 7.04M | 9.39M |
EBIT | 53.79M | 49.12M | 33.89M | 30.53M | 27.07M | 7.45M | -6.27M | -330K | -31.41M |
Net Interest Income | 658K | 1.86M | 1.75M | -896K | 335K | 450K | 511K | 0 | 511K |
Interest Income | 658K | 1.86M | 1.75M | 314K | 335K | 450K | 511K | 0 | 511K |
Interest Expense | 0 | 0 | 0 | 1.21M | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.65M | 2.95M | 2.92M | 419K | 1.36M | 894K | 689K | 943K | -25.94M |
Pretax Income | 53.79M▲ 0% | 49.12M▼ 8.7% | 33.89M▼ 31.0% | 30.95M▼ 8.7% | 27.07M▼ 12.5% | 7.45M▼ 72.5% | -6.27M▼ 184.3% | -587K▲ 90.6% | -57.36M▼ 9671.6% |
Pretax Margin % | 19.65% | 17.33% | 11.93% | 10.19% | 9.9% | 2.9% | -2.29% | -0.26% | -32.04% |
Income Tax | 16.51M | 11.38M | 8.04M | 7.03M | 5.97M | 2.31M | 1.19M | 5.68M | -73K |
Effective Tax Rate % | 30.69% | 23.17% | 23.73% | 22.72% | 22.06% | 30.96% | -18.99% | -968.31% | 0.13% |
Net Income | 37.28M▲ 0% | 37.74M▲ 1.2% | 25.85M▼ 31.5% | 23.92M▼ 7.5% | 21.1M▼ 11.8% | 5.14M▼ 75.6% | -7.46M▼ 245.2% | -6.27M▲ 16.0% | -57.29M▼ 813.5% |
Net Margin % | 13.62% | 13.32% | 9.1% | 7.88% | 7.72% | 2% | -2.72% | -2.76% | -32% |
Net Income Growth % | 56.53% | 1.23% | -31.5% | -7.47% | -11.79% | -75.64% | -245.21% | 15.98% | -813.51% |
Net Income (Continuing) | 37.28M | 37.74M | 25.85M | 23.92M | 21.1M | 5.14M | -7.46M | -6.27M | -57.29M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.82▲ 0% | 1.84▲ 1.1% | 1.29▼ 29.9% | 1.52▲ 17.8% | 1.04▼ 31.6% | 0.25▼ 76.0% | -0.37▼ 248.0% | -0.30▲ 18.9% | -2.74▼ 813.3% |
EPS Growth % | 55.56% | 1.1% | -29.89% | 17.83% | -31.58% | -75.96% | -248% | 18.92% | -813.33% |
EPS (Basic) | 1.83 | 1.84 | 1.29 | 1.53 | 1.05 | 0.25 | -0.37 | -0.30 | -2.74 |
Diluted Shares Outstanding | 20.43M | 20.49M | 20.05M | 20.12M | 20.36M | 20.34M | 20.4M | 20.6M | 20.92M |
Basic Shares Outstanding | 20.35M | 20.46M | 20.04M | 20.06M | 20.18M | 20.27M | 20.4M | 20.6M | 20.92M |
Dividend Payout Ratio | 46.86% | 58.09% | 84.34% | 94.85% | 115.56% | 477.37% | - | - | - |
PETS Balance Sheet
PetMed Express, Inc. (PETS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 105.23M | 126.43M | 129.02M | 161.19M | 151M | 130.43M | 93.65M | 78.87M | 43.56M |
Cash & Short-Term Investments | 77.94M | 100.53M | 103.76M | 118.72M | 111.08M | 104.09M | 55.3M | 54.72M | 21.41M |
Cash Only | 77.94M | 100.53M | 103.76M | 118.72M | 111.08M | 104.09M | 55.3M | 54.72M | 21.41M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 2.29M | 2.54M | 3.84M | 2.59M | 1.91M | 1.74M | 3.28M | 2.32M | 1.91M |
Days Sales Outstanding | 3.06 | 3.27 | 4.94 | 3.11 | 2.55 | 2.48 | 4.37 | 3.73 | 3.89 |
Inventory | 23.34M | 21.37M | 17.88M | 34.42M | 32.45M | 19.02M | 28.56M | 16.2M | 13.61M |
Days Inventory Outstanding | 48.4 | 41.47 | 32.18 | 57.3 | 59.8 | 37.36 | 53.07 | 37.47 | 38.56 |
Other Current Assets | 882K | 1.41M | 3.53M | 4.5M | 681K | 4.72M | 6.33M | 5.63M | 6.64M |
Total Non-Current Assets | 29.6M | 28M | 26.3M | 26.31M | 25.32M | 39.57M | 76.24M | 69.83M | 37.63M |
Property, Plant & Equipment | 28.74M | 27.14M | 25.45M | 25.45M | 24.46M | 26.18M | 28.09M | 29.82M | 26.84M |
Fixed Asset Turnover | 9.53x | 10.44x | 11.17x | 11.93x | 11.18x | 9.80x | 9.76x | 7.61x | 6.67x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 26.66M | 26.66M | 0 |
Intangible Assets | 860K | 860K | 860K | 860K | 860K | 5.86M | 11.2M | 13.35M | 10.79M |
Long-Term Investments | 0 | 0 | 25.52M | 25.55M | 24.27M | 5M | 5.3M | 0 | 5.3M |
Other Non-Current Assets | 0 | -28M | -26.3M | -26.31M | -25.32M | -5M | 4.99M | 0 | -5.3M |
Total Assets | 134.84M▲ 0% | 154.43M▲ 14.5% | 155.32M▲ 0.6% | 187.5M▲ 20.7% | 176.32M▼ 6.0% | 170M▼ 3.6% | 169.88M▼ 0.1% | 148.7M▼ 12.5% | 81.19M▼ 45.4% |
Asset Turnover | 2.03x | 1.84x | 1.83x | 1.62x | 1.55x | 1.51x | 1.61x | 1.53x | 2.20x |
Asset Growth % | 19.53% | 14.53% | 0.58% | 20.71% | -5.96% | -3.58% | -0.07% | -12.47% | -45.4% |
Total Current Liabilities | 18.11M | 18.63M | 24.34M | 44.94M | 33.2M | 57.51M | 72.16M | 62.77M | 52.03M |
Accounts Payable | 15.27M | 16.27M | 19.66M | 39.55M | 27.5M | 25.21M | 37.02M | 23.56M | 20.91M |
Days Payables Outstanding | 31.68 | 31.58 | 35.37 | 65.83 | 50.67 | 49.51 | 68.81 | 54.49 | 59.24 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 459K | 461K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 2.6M | 2.08M | 689K |
Other Current Liabilities | 431K | 613K | 1.64M | 1.83M | 4.56M | 30.74M | 30.54M | 36.66M | 29.93M |
Current Ratio | 5.81x | 6.79x | 5.30x | 3.59x | 4.55x | 2.27x | 1.30x | 1.26x | 0.84x |
Quick Ratio | 4.52x | 5.64x | 4.57x | 2.82x | 3.57x | 1.94x | 0.90x | 1.00x | 0.58x |
Cash Conversion Cycle | 19.78 | 13.16 | 1.75 | -5.43 | 11.68 | -9.67 | -11.37 | -13.29 | -16.79 |
Total Non-Current Liabilities | 996K | 1.12M | 970K | 1.28M | 936K | 2.53M | 995K | 798K | 217K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 535K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 995K | 995K | 0 | 42K |
Deferred Tax Liabilities | 996K | 1.12M | 970K | 1.28M | 936K | 2.53M | 0 | 263K | 175K |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | -995K | 0 | 0 | 0 |
Total Liabilities | 19.11M | 19.75M | 25.31M | 46.22M | 34.13M | 60.04M | 73.15M | 63.57M | 52.25M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 995K | 1.45M | 996K | 535K |
Net Debt | -77.94M | -100.53M | -103.76M | -118.72M | -111.08M | -103.09M | -53.84M | -53.72M | -20.88M |
Debt / Equity | - | - | - | - | - | 0.01x | 0.02x | 0.01x | 0.02x |
Debt / EBITDA | - | - | - | - | - | 0.10x | 15.47x | 0.18x | - |
Net Debt / EBITDA | -1.44x | -2.08x | -3.12x | -3.60x | -3.90x | -10.21x | -572.79x | -9.75x | - |
Interest Coverage | - | - | - | 25.23x | - | - | - | - | - |
Total Equity | 115.73M▲ 0% | 134.68M▲ 16.4% | 130.01M▼ 3.5% | 141.28M▲ 8.7% | 142.19M▲ 0.6% | 109.97M▼ 22.7% | 96.73M▼ 12.0% | 85.13M▼ 12.0% | 28.94M▼ 66.0% |
Equity Growth % | 23.95% | 16.37% | -3.47% | 8.67% | 0.64% | -22.66% | -12.04% | -11.99% | -66.01% |
Book Value per Share | 5.66 | 6.57 | 6.48 | 7.02 | 6.98 | 5.41 | 4.74 | 4.13 | 1.38 |
Total Shareholders' Equity | 115.73M | 134.68M | 130.01M | 141.28M | 142.19M | 109.97M | 96.73M | 85.13M | 28.94M |
Common Stock | 21K | 21K | 20K | 20K | 21K | 21K | 21K | 21K | 21K |
Retained Earnings | 106.32M | 122.17M | 126.18M | 134.14M | 130.5M | 91.66M | 71.56M | 66.54M | 9.26M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -6.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PETS Cash Flow Statement
PetMed Express, Inc. (PETS) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 37.38M | 45.14M | 38.84M | 40.08M | 18.5M | 27.8M | 4.32M | 4.72M | -28.39M |
Operating CF Margin % | 13.65% | 15.93% | 13.67% | 13.2% | 6.77% | 10.84% | 1.57% | 2.08% | -15.86% |
Operating CF Growth % | -20.81% | 20.76% | -13.94% | 3.17% | -53.84% | 50.3% | -84.47% | 9.29% | -701.82% |
Net Income | 37.28M | 37.74M | 25.85M | 30.6M | 21.1M | 233K | -7.46M | -6.27M | -57.29M |
Depreciation & Amortization | 2.13M | 2.23M | 2.26M | 2.43M | 2.74M | 3.55M | 7.06M | 7.04M | 9.39M |
Stock-Based Compensation | 2.58M | 3.1M | 2.82M | 3.31M | 4.55M | 6.62M | 6.87M | -6.59M | 1.36M |
Deferred Taxes | -92K | 125K | -151K | 311K | -345K | -1.56M | 292K | 5.25M | -88K |
Other Non-Cash Items | 112K | 85K | 191K | 130K | 165K | 5.05M | 324K | 1.56M | 26.62M |
Working Capital Changes | -4.63M | 1.87M | 7.87M | 3.3M | -9.71M | 13.92M | -2.76M | 3.72M | -8.39M |
Change in Receivables | -596K | -335K | -1.49M | 1.13M | 509K | -41K | -1.74M | 601K | 445K |
Change in Inventory | -3.11M | 1.97M | 3.49M | -16.54M | 1.97M | 13.43M | -6.42M | 12.35M | 471K |
Change in Payables | 53K | 1M | 3.38M | 19.89M | -12.05M | -2.29M | 6.1M | -13.46M | -2.66M |
Cash from Investing | -703K | -620K | -2.31M | -2.43M | -1.75M | -10.26M | -40.67M | -5.11M | -4.62M |
Capital Expenditures | -703K | -620K | -2.31M | -2.43M | -1.75M | -5.26M | -4.51M | -5.11M | -4.62M |
CapEx % of Revenue | 0.26% | 0.22% | 0.81% | 0.8% | 0.64% | 2.05% | 1.65% | 2.25% | 2.58% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -5M | -36.16M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 5M | 0 | 0 | 0 |
Cash from Financing | -17.47M | -21.93M | -33.3M | -22.69M | -24.38M | -24.54M | -12.44M | -181K | -299K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | -11.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Dividends Paid | -17.47M | -21.93M | -21.8M | -22.69M | -24.38M | -24.54M | -12.44M | -181K | -21K |
Share Repurchases | 0 | 0 | -11.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -278K |
Net Change in Cash | 19.21M▲ 0% | 22.59M▲ 17.6% | 3.23M▼ 85.7% | 14.96M▲ 362.6% | -7.64M▼ 151.1% | -6.99M▲ 8.4% | -48.79M▼ 597.6% | -576K▲ 98.8% | -33.31M▼ 5682.6% |
Free Cash Flow | 36.68M▲ 0% | 44.52M▲ 21.4% | 36.53M▼ 17.9% | 37.64M▲ 3.0% | 16.75M▼ 55.5% | 22.54M▲ 34.6% | -194K▼ 100.9% | -395K▼ 103.6% | -33.01M▼ 8256.7% |
FCF Margin % | 13.4% | 15.71% | 12.86% | 12.4% | 6.12% | 8.79% | -0.07% | -0.17% | -18.44% |
FCF Growth % | 0.21% | 21.38% | -17.94% | 3.04% | -55.51% | 34.62% | -100.86% | -103.61% | -8256.71% |
FCF per Share | 1.79 | 2.17 | 1.82 | 1.87 | 0.82 | 1.11 | -0.01 | -0.02 | -1.58 |
FCF Conversion (FCF/Net Income) | 1.00x | 1.20x | 1.50x | 1.68x | 0.88x | 5.41x | -0.58x | -0.75x | 0.50x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 18.05M | 11.05M | 7.14M | 10.02M | 6.08M | 4.31M | 130K | 0 | 52K |
PETS Key Ratios
PetMed Express, Inc. (PETS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 26.98% | 35.66% | 30.14% | 19.53% | 17.63% | 14.89% | 4.08% | -7.22% | -6.9% | -100.44% |
Return on Invested Capital (ROIC) | 70.11% | 107.97% | 96.27% | 76.93% | 93.82% | 71.86% | 25.87% | -20.98% | -3.09% | -119.38% |
Gross Margin | 31.83% | 35.72% | 33.63% | 28.6% | 27.77% | 27.55% | 27.68% | 28.35% | 30.46% | 28.05% |
Net Margin | 9.56% | 13.62% | 13.32% | 9.1% | 7.88% | 7.72% | 2% | -2.72% | -2.76% | -32% |
Debt / Equity | - | - | - | - | - | - | 0.01x | 0.02x | 0.01x | 0.02x |
Interest Coverage | - | - | - | - | 25.23x | - | - | - | - | - |
FCF Conversion | 1.98x | 1.00x | 1.20x | 1.50x | 1.68x | 0.88x | 5.41x | -0.58x | -0.75x | 0.50x |
Revenue Growth | 6.18% | 9.88% | 3.51% | 0.25% | 6.85% | -9.94% | -6.16% | 6.83% | -17.19% | -21.13% |
Related:PETS Dividend History·PETS Revenue History·PETS Price History·PETS P/E History·PETS Financial Ratios·PETS Institutional Holders
PETS SEC Filings & Documents
PetMed Express, Inc. (PETS) SEC filings — annual & quarterly reports (10-K, 10-Q)
PETS Frequently Asked Questions
PetMed Express, Inc. (PETS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PetMed Express, Inc. (PETS) reported $179.0M in revenue for fiscal year 2026. This represents a 1120% increase from $14.7M in 2000.
PetMed Express, Inc. (PETS) saw revenue decline by 21.1% over the past year.
PetMed Express, Inc. (PETS) reported a net loss of $57.3M for fiscal year 2026.
Dividend & Returns
PetMed Express, Inc. (PETS) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
PetMed Express, Inc. (PETS) has a return on equity (ROE) of -100.4%. Negative ROE indicates the company is unprofitable.
PetMed Express, Inc. (PETS) had negative free cash flow of $33.0M in fiscal year 2026, likely due to heavy capital investments.